Impact of COVID-19 pandemic on cardiometabolic patients without SARS CoV-2 infection in Latin America

A cross-sectional survey including 38 questions about demography, clinical condition, changes in health habits, and medical treatments for cardiometabolic patients in outpatient follow-up was conducted. From June 15 to July 15, 2020, a total of 13 Latin-American countries participated in enrolling patients. These countries were divided into 3 geographic regions: Region 1 including North, Central, and Caribbean Regions (NCCR), Region 2 including the Andean Region (AR), and Region 3 including the Southern Cone Region (SCR). 4.216 patients were analyzed, resulting in a coefficient of 33.82%, 32.23%, and 33.94% for NCCR, AR, and SCR, respectively. Significant differences were found between the AR, SCR, and NCCR regions. The analysis of habitual medication usage showed that discontinued use of medication was more present in AR, reaching almost 30% (p < 0.001). The main finding of this study was the negative impact that restrictive measures have on adherence to medications and physical activity: Rs = 0.84 (p = 0.0003) and Rs = 0.61 (p = 0.0032), respectively. AR was the most vulnerable region. Restrictive quarantine measures imposed by the different countries showed a positive correlation with medication discontinuation and a negative correlation with physical activity levels in patients analyzed. These findings characterize the impact of the consequences left by this pandemic. Undoubtedly, restrictive measures have been and will continue to have reverberating negative effects in most Latin-American countries.Fil: Camiletti, Jorge. Hospital Italiano de La Plata; ArgentinaFil: Renna, Nicolas Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Fisiología Patológica; Argentina. Hospital Español de Mendoza; ArgentinaFil: López Santi, Ricardo. Hospital Italiano de La Plata; ArgentinaFil: Erriest, Juan. Hospital Italiano de La Plata; ArgentinaFil: García-Bello, Eliomar. Centro de Diagnóstico Medicina Avanzada y Telemedicina; República DominicanaFil: Araujo, John. Centro Cardiovascular Somer Incare; ColombiaFil: Varleta-Olivares, Paola. Hospital Dipreca; ChileFil: Gómez-Díaz, Eduardo. Hospital Metropolitano del Norte; VenezuelaFil: Ramírez, Gisselle. Medicina Cardiovascular Asociada; República DominicanaFil: Berni Betancourt, Ana. Sociedad interamericana de Cardiología; México. Consejo Interamericano de Electrocardiográfica y Arritmias; México. Hospital Ángeles Pedregal; MéxicoFil: Escalada Lesme, Gustavo. Centro Médico Nacional-Hospital Nacional Itaguá; ParaguayFil: Campos Alcántara, Lourdes V.. Consultorio de Lourdes Victoria Campos Alcántara; PerúFil: Moya Loor, Leonardo. Hospital Santa Margarita; EcuadorFil: Rey Benavente, Claudio. Hospital Arroyabe Pichanal; ArgentinaFil: Almonte, Claudia. Medicina Cardiovascular Asociada; República DominicanaFil: Cortez Sandoval, Maicol. Hospital Nacional Edgardo Rebagliti Martins; PerúFil: Alvarado Cuadros, María. Department of Cardiology, Institution; EcuadorFil: Rosario, Monica I.. Centro de Diagnóstico Medicina Avanzada y Telemedicina; República DominicanaFil: Gupta, Shyla. Queen’s University; CanadáFil: Ibarrola, Martin. Cardiovascular Center BV; ArgentinaFil: Baranchuk, Adrián. Kingston Health Sciences Centre; Canad

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Exámenes diagnósticos cardiovasculares: ¿diferencias de género en su interpretación?

Resumen: Dado que la enfermedad cardiovascular es la principal causa de muerte en las mujeres, conocer las diferencias de género que existen en su diagnóstico, tratamiento y evolución resulta fundamental para el enfoque de la intervención. El rol de las técnicas no invasivas en la evaluación de las mujeres con sospecha de enfermedad cardiovascular isquémica debe tener en cuenta las diferencias anatómicas, fisiológicas y patológicas, que están directamente relacionadas con las diferencias en sus resultados e interpretación. La prueba de esfuerzo convencional tiene menor sensibilidad y especificidad en las mujeres que en los hombres, mientras que la prueba de perfusión miocárdica con talio tiene una sensibilidad más alta, pero no una especificidad mejor al electrocardiograma de esfuerzo tradicional en mujeres, y el Tc-99 sestamibi SPECT tiene una especificidad del â¼90% en mujeres, la cual es similar a la del hombre. Pruebas como el ecocardiograma de estrés tienen una sensibilidad ligeramente peor en mujeres versus hombres, pero con una especificidad comparable. La resonancia nuclear magnética (RNM) y la angioTAC coronaria tienen en la actualidad un papel preponderante en el estudio de la enfermedad isquémica cardiaca. La sospecha clínica de enfermedad cardiovascular en la mujer, sumado a la escogencia de la mejor técnica diagnóstica y la interpretación adecuada, favorece diagnósticos y tratamientos más oportunos. Abstract: Given that cardiovascular disease is the main cause of death in women, awareness of the gender differences in its diagnosis, treatment and development is essential for intervention. The role of non-invasive techniques in the assessment of women with suspected ischemic heart disease should take into account the anatomical, physiological and pathological differences which are directly related to their results and interpretation. Conventional stress tests have less sensitivity and specificity in women than in men, while thallium myocardial perfusion scans have a higher sensitivity, but not a better specificity, than the conventional stress electrocardiogram in women; and the Tc-99 sestamibi SPECT has a â¼90% specificity in women, which is similar to that in men. Tests such as stress echocardiograms have a slightly worse sensitivity in women versus men, with a comparable specificity. Nuclear magnetic resonance (NMR) and coronary CT angiography currently have a preponderant role in the study of ischemic heart disease. The clinical suspicion of cardiovascular disease in women, together with the selection of the best diagnostic technique and an adequate interpretation, favors more timely diagnoses and treatments. Palabras clave: Enfermedad cardiovascular, Diagnóstico, Cardiopatía isquémica, Mujer, Keywords: Cardiovascular disease, Diagnosis, Ischemic heart disease, Woma

Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor

High sensitivity C-reactive protein (hsCRP) is a marker of metabolic syndrome (MS) and cardiovascular (CV) disease. Lipoprotein-associated phospholipase A2 (Lp-PLA2) also predicts CV disease. There are no reports comparing these markers as predictors of MS. Methods. Cross-sectional study comparing Lp-PLA2 and hsCRP as predictors of MS in asymptomatic subjects was carried out; 152 subjects without known atherosclerosis participated. Data were collected on demographics, cardiovascular risk factors, anthropometric and biochemical measurements, and hsCRP and Lp-PLA2 activity levels. A logistic regression analysis was performed with each biomarker and receiver operating characteristic (ROC) curves were constructed for MS. Results. Mean age was 46 ± 11 years, and 38% of the subjects had MS. Mean Lp-PLA2 activity was 185 ± 48 nmol/mL/min, and mean hsCRP was 2.1 ± 2.2 mg/L. Subjects with MS had significantly higher levels of Lp-PLA2 (P=0.03) and hsCRP (P<0.0001) than those without MS. ROC curves showed that both markers predicted MS. Conclusion. Lp-PLA2 and hsCRP are elevated in subjects with MS. Both biomarkers were independent and significant predictors for MS, emphasizing the role of inflammation in MS. Further research is necessary to determine if inflammation predicts a higher risk for CV events in MS subjects

Assessment of adherence to antihypertensive therapy Prevalencia y determinantes de adherencia a terapia antihipertensiva en pacientes de la Región Metropolitan

© 2015 Sociedad Medica de Santiago. All Rights Reserved.Background: Lack of adherence with medications is the main cause of antihypertensive treatment failure. Aim: To assess adherence to antihypertensive drugs and its determinants. Material and Methods: The Morinsky-Green questionnaire to determine treatment adherence was applied to 310 hypertensive patients from primary care centers, aged 60 ± 10 years (65% females) in treatment for 4 ± 1 months. Socio-demographic features, use of medications and quality of life using EQ5D questionnaire were also assessed. Results: Twenty percent of patients were diabetic and 19% were smokers. Fifty four percent were adherent to therapy. A higher age and being unemployed were associated with a higher compliance. The main reasons to justify the lack of adherence were forgetting to take the pills in 67% and adverse effects in 10%. Only diastolic pressure was lower in adherent patients, compared with their non-adherent counterparts (78 ± 12 and 81 ± 1

Interventricular Septal Hematoma Complicating Left Branch Bundle Lead Implantation

We present a female patient with heart failure with reduced ejection fraction who underwent left bundle branch cardiac resynchronization therapy. Left bundle branch lead implantation was complicated with septal branch perforation causing an iatrogenic coronary fistula complicated by septal hematoma formation and development of shock. Occlusion by covered stents was successfully achieved. (Level of Difficulty: Advanced.